Should I Buy GH? GH 2026 Analysis

Should You Buy Guardant Health Inc (GH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

101.850

1 Day change

3.55%

52 Week Range

120.740

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now (dip-entry): The stock just sold off hard (-6.47% regular session) into/near support while fundamentals and Street narrative are improving (FDA milestone, Merck collaboration, positive FCF).
Setup favors a rebound trade: Near-term technicals are oversold-ish and sitting above S1 support (~~104.9). Upside mean-reversion targets are the pivot (~~112) then ~119.
Sentiment skew is constructive: Options positioning is call-leaning (put/call < 1), and analysts have been raising targets aggressively.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Bearish momentum remains in force (MACD histogram -0.865 and negatively expanding), consistent with the sharp selloff.
RSI (6): 29.17, signaling short-term oversold/washed-out conditions that often precede bounces.
Moving averages: Converging MAs suggest the stock is at an inflection area rather than a clean uptrend.
Key levels:
- Pivot: 111.97 (reclaiming this improves near-term trend)
- Support: 104.90 (S1) then 100.52 (S2)
- Resistance: 119.05 (R1) then 123.43 (R2)
Pattern-based forward odds (provided): Similar-pattern stats imply modest next-day drift (+0.27%) but weakness over 1 week (-3.12%) and 1 month (-2.29%), so this is best framed as a rebound/mean-reversion buy, not a confirmed trend reversal yet.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/call ratios below 1 (OI 0.71; volume 0.89) indicate more call interest than put interest, i.e., a cautiously bullish tilt.
Volatility: 30D IV 74.4 vs historical vol 39.1; IV percentile 76.9 = options are pricing elevated move risk (often around catalysts).
Flow intensity: Today’s option volume 332 is only 28.6% of the 30D average (muted activity), suggesting sentiment is not driven by a major one-day options rush.
Open interest: Total OI 18,649 (calls 10,921 vs puts 7,728) supports a call-leaning structure.

Technical Summary

Sell

Buy

Positive Catalysts

- Fundamental/news tone is positive: multi-year collaboration with Merck, FDA approval for Guardant360 CDx in colorectal cancer, and positive free cash flow (Q3 2025) cited in the news.
- Analyst momentum: Multiple target raises in January 2026, including a major move from UBS to $175.
- Upcoming event: QDEC 2025 earnings on 2026-02-19 (after hours) can act as a near-term catalyst if revenue growth/margins hold and cash flow narrative continues.

Neutral/Negative Catalysts

- Price action damage: The -6.47% regular-session drop plus bearish MACD suggests sellers still have control near-term.
- Event risk ahead: Earnings on 2026-02-19 can cut either way; with elevated IV, the market is pricing a meaningful move.
- No confirming “must-buy” quant signal today: Intellectia modules show no AI Stock Picker and no SwingMax entry signal, so this is not a top-priority systematic entry.

Financial Performance

Latest reported quarter: 2025/Q3
Revenue: $265.2M, +38.5% YoY (strong top-line acceleration).
Gross margin: 64.71%, +5.91% YoY (quality of growth improving).
Profitability: Net income -$92.7M (loss deepened vs prior year per provided change), EPS -0.74 (worse YoY). The story remains growth + improving margin, but still not yet consistently profitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Predominantly bullish with repeated price target raises through January 2026 (TD Cowen to $130, Stifel to $120, Mizuho to $135, Guggenheim to $135, UBS to $175).
Notable counterpoint: Evercore ISI downgraded to In Line with PT $105 (near current price), signaling some concern after the run-up/valuation or near-term execution.
Wall Street “pros” view: Strong growth drivers, FDA/reimbursement milestones, and strategic partnerships (e.g., Merck) support upside.
Wall Street “cons” view: Ongoing losses and reliance on catalysts/reimbursement timing keep some firms cautious despite growth.
Influential/political trading: No recent congress trading data available; hedge funds/insiders noted as neutral with no significant recent trend.

19 Analyst Rating

Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105 USD and a high forecast of 155 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Buy

1 Hold

0 Sell

Strong Buy

Current: 98.360

Low

105

Averages

124.69

High

155

Current: 98.360

Low

105

Averages

124.69

High

155

UBS

NULL -> Buy

upgrade

$110 -> $175

AI Analysis

2026-01-30

Reason

UBS

Price Target

$110 -> $175

AI Analysis

2026-01-30

upgrade

NULL -> Buy

Reason

UBS raised the firm's price target on Guardant Health to $175 from $110 and keeps a Buy rating on the shares. Guardant Health's strong growth drivers, FDA milestones, and Medicare reimbursement opportunities position it uniquely in diagnostics, the analyst tells investors in a research note.

Guggenheim

NULL -> Buy

upgrade

$115 -> $135

2026-01-26

Reason

Guggenheim

Price Target

$115 -> $135

2026-01-26

upgrade

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Guardant Health to $135 from $115 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GH

Unlock Now

GH Should I Buy

GH Should I Buy

Should You Buy Guardant Health Inc (GH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch